Product information and disease descriptionPlace of product in therapyDisease description
Definition and etiology
9 evidence topics · 6 sources
Steatotic liver disease nomenclature: MASLD replaces NAFLD and MASH replaces NASH
“Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 75% of respondents of the external expert committee chose MASLD as the replacement term for NAFLD and 88% metabolic dysfunction–associated steatohepatitis (MASH) as the replacement term for NASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Persons with MASLD and steatohepatitis will be designated as metabolic dysfunction associated steatohepatitis (MASH).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MASLD as a disease spectrum from steatosis to MASH, fibrosis, cirrhosis, and hepatocellular carcinoma
“Metabolic dysfunction-associated steatotic liver disease (MASLD) is the umbrella term that comprises metabolic dysfunction-associated steatotic liver, or isolated hepatic steatosis, through to metabolic dysfunction-associated steatohepatitis, the progressive necroinflammatory disease form that can progress to fibrosis, cirrhosis and hepatocellular carcinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MASLD is closely associated with insulin resistance, obesity, gut microbial dysbiosis and genetic risk factors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fibrosis staging retained under the new nomenclature, including MASH with stage 3 fibrosis
“The new names also allow for further characterisation of fibrotic severity, for example, MASH with stage 3 fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disease staging and severity are not altered by this process although it is anticipated that, in the near to medium term, disease staging will be achieved using noninvasive tests, which can be incorporated into further clarifications of disease stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
At-risk NASH defined as biopsy-proven NASH with stage 2 or higher fibrosis
Continuity of NAFLD and NASH evidence with MASLD and MASH: European registry and US NHANES overlap
“an analysis of the LITMUS consortium European was performed, which demonstrated that 98% of the existing registry cohort of patients with NAFLD would fulfill the new criteria for MASLD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“maintenance of the term, and clinical definition, of steatohepatitis ensures retention and validity of prior data from clinical trials and biomarker discovery studies of patients with NASH to be generalisable to individuals classified as MASLD or MASH under the new nomenclature, without impeding the efficiency of research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was 99% overlap in cases of NAFLD and MASLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among those with NAFLD or MASLD, 99.0% (95% CI 97.6%–99.6%) met the criteria for both NAFLD and MASLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiometabolic risk factors in the definition of MASLD: adult criteria
| Metabolic risk factor | Adult criteria |
|---|---|
| Overweight or obesity: body mass index | “≥25 kg/m2 (≥23 kg/m2 in people of Asian ethnicity)” |
| Overweight or obesity: waist circumference (Europeans) | “≥94 cm in men and ≥80 cm in women (Europeans)” |
| Overweight or obesity: waist circumference (South Asians and Chinese) | “≥90 cm in men and ≥80 cm in women (South Asians and Chinese)” |
| Dysglycaemia: prediabetes | “Prediabetes: HbA1c 39-47 mmol/mol (5.7-6.4%) or fasting plasma glucose 5.6-6.9 mmol/L (100-125 mg/dl)” |
| Type 2 diabetes | “Type 2 diabetes: HbA1c ≥48 mmol/mol (≥6.5%) or fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dl)”; “Treatment for type 2 diabetes” |
| Plasma triglycerides | “≥1.7 mmol/L (≥150 mg/dl) or lipid-lowering treatment” |
| HDL-cholesterol | “≤1.0 mmol/L (≤39 mg/dl) in men and ≤1.3 mmol/L (≤50 mg/dl) in women or lipid-lowering treatment” |
| Blood pressure | “≥130/85 mmHg or treatment for hypertension” |
Alcohol intake thresholds separating MASLD, MetALD, and alcohol-related liver disease
Etiology: type 2 diabetes, obesity, age, and menopausal status as risk factors for progressive fibrosis
“T2DM is the most impactful risk factor for the development of NAFLD, fibrosis progression, and HCC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NAFLD is closely linked to and often precedes the development of metabolic abnormalities (insulin resistance, dyslipidemia, central obesity, and hypertension).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: inherited risk, PNPLA3 and TM6SF2 variants, and heritability
“NAFLD and NASH have a heritable component that is estimated to be between 35%–61%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PNPLA3 gene is a major driver of NAFLD, NASH, cirrhosis, and HCC risk in individuals who have metabolic risk factors such as obesity, diabetes, and metabolic syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote